The GLP-1 analogue liraglutide reduced kidney fibrosis in diabetic mice by inhibiting ferroptosis (iron-dependent cell death) through the Fsp1-CoQ10-NAD(P)H antioxidant pathway.
Ferroptosis blocked via Fsp1-CoQ10-NAD(P)HLiraglutide activated the Fsp1-CoQ10-NAD(P)H antioxidant pathway — an iron-death defense system independent of the more studied GPX4 pathway — reducing kidney iron deposits, lipid peroxidation, and fibrosis.
What the researchers found
In db/db diabetic mice treated with liraglutide (200 µg/kg/day for 6 weeks), multiple kidney-protective effects were observed:
- Improved renal function and reduced kidney fibrosis
- Upregulated antioxidant enzymes (T-SOD, GSH-Px, GSH)
- Reduced oxidative damage markers (8-OHDG, MDA, LPO, 4-HNE, 12-Lox, NOX4)
- Decreased iron deposition via reduced TfR1 (iron import) and increased FPN1 (iron export)
- Inhibited ferroptosis through activation of the Fsp1-CoQ10-NAD(P)H pathway
In vitro experiments confirmed that liraglutide protected cells from high glucose-induced viability decline and lipid peroxidation through the same pathway.
Why it matters
Diabetic kidney disease is the leading cause of kidney failure worldwide, and fibrosis is the final common pathway of kidney damage. Identifying that liraglutide protects kidneys by blocking ferroptosis through a specific molecular pathway provides a mechanistic explanation for the clinical kidney benefits already observed in GLP-1 drug trials. This could lead to more targeted therapies and help identify which patients might benefit most from GLP-1 kidney protection.
How the study worked
Researchers used db/db mice (a genetic model of type 2 diabetes) and treated them with daily intraperitoneal liraglutide injections (200 µg/kg/day) for 6 weeks. They assessed kidney function, histopathology, lipid peroxidation levels, iron accumulation, and ferroptosis markers. Antioxidant enzyme activities and oxidative stress markers were measured. Iron metabolism was evaluated by examining transferrin receptor 1 (TfR1) and ferroportin 1 (FPN1) expression. The Fsp1-CoQ10-NAD(P)H pathway was investigated both in vivo and in complementary in vitro experiments using high-glucose-treated cells.
What this study cannot tell us
The study was conducted entirely in mice (db/db model) and cell culture, which may not perfectly replicate human diabetic kidney disease. The db/db mouse is a severe genetic model of obesity-driven diabetes that differs from typical human type 2 diabetes. The 6-week treatment period is relatively short for assessing fibrosis outcomes. Liraglutide was administered intraperitoneally rather than subcutaneously (the human route). The study did not compare against other GLP-1 drugs or include a ferroptosis-specific positive control to confirm pathway specificity.
How to read the evidence
This is a preclinical mechanistic study using a standard diabetic mouse model with both in vivo and in vitro validation. The comprehensive assessment of multiple ferroptosis markers and pathway components is a strength, though all findings are in rodent/cell systems and have not been confirmed in humans.
When this study was published
Published in 2025, this is a very recent study contributing to the rapidly expanding understanding of how GLP-1 drugs protect organs beyond their metabolic effects. Ferroptosis research is a fast-moving field.
The bigger picture
Ferroptosis is a newly recognized form of cell death that is gaining attention across many diseases, including cancer, neurodegeneration, and now diabetic kidney disease. The discovery that a widely prescribed GLP-1 peptide drug inhibits ferroptosis through a specific antioxidant pathway adds to the growing understanding of why GLP-1 drugs have benefits far beyond blood sugar control. The Fsp1-CoQ10-NAD(P)H pathway represents a GPX4-independent ferroptosis defense system, expanding the known mechanisms of GLP-1 kidney protection.
Questions still open
- Does this ferroptosis-inhibiting mechanism apply to other GLP-1 receptor agonists like semaglutide and tirzepatide?
- Could measuring ferroptosis biomarkers in diabetic patients help identify who will benefit most from GLP-1 kidney protection?
- Would combining liraglutide with other ferroptosis inhibitors provide additive kidney protection in diabetes?
Common questions
What is ferroptosis and how does it damage kidneys in diabetes?
Does this mean liraglutide protects kidneys beyond just lowering blood sugar?
Read the original research
Exploring Liraglutide's mechanism in reducing renal fibrosis: the Fsp1-CoQ10-NAD(P)H pathway.
Scientific reports, 15(1), 1754
Citation
Chen, Qi; Song, Ji-Xian; Zhang, Zhi; An, Ji-Ren; Gou, Yu-Jing; Tan, Miao; Zhao, Yashuo. (2025). Exploring Liraglutide's mechanism in reducing renal fibrosis: the Fsp1-CoQ10-NAD(P)H pathway.. Scientific reports, 15(1), 1754. https://doi.org/10.1038/s41598-025-85658-z